GSK•benzinga•
GSK Announces Its GLISTEN Study Met Its Primary Endpoint, With Linerixibat Resulting In An Improvement In Itch
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga